Sinopharm’s EUA application now under FDA review | Inquirer

Sinopharm’s EUA application now under FDA review

By: - Reporter /
/ 11:36 AM March 02, 2021

MADE IN CHINA The Beijing Institute of Biological Products claims the Sinopharm vaccine is 79 percent effective. —REUTERS

MANILA, Philippines — China state-owned firm Sinopharm has applied for its Covid-19 vaccine’s emergency use authorization (EUA) in the Philippines, the Food and Drug Administration (FDA) confirmed Tuesday.

FDA Director General Eric Domingo said they are in the process of reviewing Sinopharm’s documents.

Article continues after this advertisement

“An online application was filed yesterday afternoon and the FDA is checking the contents of the submission now,” Domingo told in a text message.

FEATURED STORIES

It was presidential spokesperson Harry Roque who announced Sinopharm’s application for an EUA, but the FDA was not able to confirm it immediately.

Roque has said Sinopharm’s vaccine is the one preferred by President Rodrigo Duterte. It was also endorsed by Duterte’s special envoy to China Ramon Tulfo, who had recently admitted to having received vaccine jobs in October, along with other unnamed Cabinet officials.

Article continues after this advertisement

The FDA has so far given an EUA to only three vaccines developed by Pfizer-BioNTech, AstraZeneca and Sinovac.

Meanwhile, the EUA application of India’s Bharat Biotech and Russia’s Gamaleya Research Institute remain under evaluation.

EDV
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the and acknowledge that I have read the .

globalnation
globalnation
opinion
business
technology
www
entertainment
business
globalnation
TAGS: Sinopharm

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the and acknowledge that I have read the .

© Copyright 1997-2024 | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies.